Publication venue
Publication date 01/01/2009
Field of study Get PDF Performance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text
Publication venue 'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study No full text